In addition, AT‐LXA4 and LXB4 have demonstrated efficacy in lowering severity of infant eczema (Wu et al., 2013), while an inhaled LXA4 mimetic, 5(S),6(R)‐LXA4 methyl ester and the LTA4 agonist, BML‐11, have both yield positive outcomes in acute and moderate episodes of asthma in children (Kong et al., 2017). The gene discussed is LTA4H; the disease is Eczematoid dermatitis.